Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects

This study has been terminated.
(Interim review indicated that the dose selected was too high for diabetics)
Information provided by (Responsible Party):
Evolva SA Identifier:
First received: March 8, 2012
Last updated: June 14, 2013
Last verified: June 2013

The principal objective of this study is to evaluate the safety and tolerability of repeated doses of EV-077-3201-2TBS given to diabetic subjects over a 4 week treatment period. The secondary aim of this initial Phase IIa study is to evaluate the effect of multiple oral doses of EV-077-3201-2TBS on platelet function, vascular function, vascular inflammation, vascular oxidative stress, renal function and a selection of exploratory parameters and biomarkers in type 2 diabetic subjects, as well as multiple dose pharmacokinetics in diabetic subjects.

In order to ensure the safety of the diabetic subjects, initial parts of the study will evaluate the safety and tolerability of EV-077-3201-2TBS. In Part A, the safety of different doses EV-077-3201-2TBS will be investigated in healthy subjects treated for 4 weeks. In parallel, Part B will investigate potential interactions between EV-077-3201-2TBS and ASA in healthy subjects. Part C will then investigate the safety, pharmacokinetics and pharmacodynamics of EV-077-3201-2TBS in type 2 diabetic subjects with and without concomitant ASA therapy.

Condition Intervention Phase
Type 2 Diabetes
Drug: EV-077
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Double-blind, Controlled Study in Healthy and Type 2 Diabetic Subjects to Assess Safety, Tolerability and Pharmacokinetics of 28 Days EV-077 Treatment, and the Effects on Platelet Function, Vascular Inflammation and Oxidative Stress.

Further study details as provided by Evolva SA:

Primary Outcome Measures:
  • Platelet aggregation [ Time Frame: 8 days ]
    Measured at Day 8 by Multiplate® with arachidonic acid as the agonist

Secondary Outcome Measures:
  • Platelet aggregation [ Time Frame: Days 1, 2, 8, 15, 22 and 29 ]
    Measured at multiple time points by Multiplate (using arachidonic acid, collagen, U-46619 and ADP as agonists) and the Born method (using arachidonic acid, collagen and ADP as agonists)

  • Vascular inflammatory state [ Time Frame: Baseline, 2 weeks and 4 weeks ]
    Changes from baseline in markers of platelet function, vascular function, vascular inflammation and vascular oxidative stress

  • Diabetic state [ Time Frame: Baseline, 2 weeks and 4 weeks ]
    Change from baseline in fasting plasma glucose and HbA1c

  • Renal function [ Time Frame: Baseline, 2 weeks and 4 weeks ]
    Change from baseline in urinary albumin excretion, creatinine clearance and exercise-induced microalbuminuria

Enrollment: 33
Study Start Date: January 2012
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: EV-077
Oral administration
Drug: EV-077
twice daily oral administration
Other Name: EV-077-3201-2TBS
Placebo Comparator: Placebo
Oral administration
Drug: Placebo
twice daily oral administration


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subjects aged 18 to 70 years inclusive. (NB. All females must be of non-reproductive potential, i.e. post-menopausal, post-hysterectomy, bilateral tubal ligation or bilateral oophorectomy).
  • Body mass index (BMI) between 25.0 and 40.0 kg/m2 (both inclusive).
  • Subjects with type 2 diabetes mellitus according to American Diabetes Association (ADA) definition for a duration of at least 3 years, on a stable therapy with oral anti-diabetic drugs (OAD) or with insulin, with or without one or two OADs or a glucagon like peptide-1 (GLP-1) agonist, or glitazones. Stable baseline therapy is defined as unchanged dose regimen for at least 3 months before administration of the study drug.
  • HbA1c ≥ 6.0 and ≤ 9.0 %.
  • History of hyperlipidaemia, with either elevated LDL cholesterol (>140 mg/dL) without therapy, or treatment with statins (NB. Patients on statin therapy must have a 2 week wash-out before they can enter the study).
  • History of hypertension, either with systolic blood pressure levels between 140 to 160 mmHg without treatment, or treatment with ACE inhibitors or ARB, which should be stable over the previous 3 months.

Exclusion Criteria:

  • Abnormal and clinically significant ECG at screening.
  • Donation of any blood or plasma in the past month or in excess of 500 mL within the 12 weeks preceding screening.
  • Intake of paracetamol within 7 days before start of treatment.
  • Surgery or trauma with significant blood loss within the last 3 months before administration of study drug.
  • Smokers (negative cotinine test required).
  • Clinically significant abnormal laboratory test results during the screening as judged by the Investigator (one retest within a week is permitted, the last result being conclusive).
  • Increased risk of bleeding, e.g. subjects with a history of deep cerebral bleeding or known defects of haemostasis with increased risk of bleeding, as judged by the Investigator.
  • History of or presence of clinically significant diseases such as cancer, clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, psychiatric diseases, other major disorders as judged by the Investigator, or significant secondary diabetic complications, such as but not limited to clinically relevant peripheral neuropathy, retinopathy, diabetic foot ulcers, as judged by the Investigator.
  • Supine blood pressure at screening, after resting for 5 min, of > 160 mmHg systolic or > 95 mmHg diastolic (excluding white-coat hypertension; therefore, if a repeat measurement on a second screening visit shows values within the range, the subject can be included in the trial).
  • Type 1 diabetes mellitus.
  • Intake of anti-inflammatory drugs except ASA (dose 75-125mg/day stable for the previous 3 months) within 14 days before start of treatment. Steroid therapy other than topical application is not allowed.
  • Any treatment with diuretics (hydrochlorothiazide is allowed)
  • Liver enzymes (ALT and AST) more than 1.5 times the upper limit of normal.
  • Any contraindication for a therapy with ASA such as allergy to ASA, including asthma, acute gastric ulcers, haemorrhagic diathesis, renal or liver insufficiency, or heart failure.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01551381

Profil Institut für Stoffwechselforschung GmbH
Neuss, Germany
Sponsors and Collaborators
Evolva SA
Principal Investigator: Thomas Jax, MD Profil Institut für Stoffwechselforschung GmbH, Germany
  More Information

Responsible Party: Evolva SA Identifier: NCT01551381     History of Changes
Other Study ID Numbers: EV077/C005
2011-003808-20 ( EudraCT Number )
Study First Received: March 8, 2012
Last Updated: June 14, 2013

Keywords provided by Evolva SA:
Pharmacodynamics processed this record on April 24, 2017